Galectin 1 hFc Chimera, Mouse
| $340.00 | |
| Z06132-100 | |
|
|
|
|
|
|
|
|
|
| Ask us a question | |
IVD Raw Materials
| $340.00 | |
| Z06132-100 | |
|
|
|
|
|
|
|
|
|
| Ask us a question | |
| Species | Mouse | ||||
| Protein Construction |
|
||||
| Purity | > 95% as determined by BisTris PAGE | ||||
| Endotoxin Level | Less than 1EU per μg by the LAL method. | ||||
| Expression System | HEK293 | ||||
| Theoretical Molecular Weight | 42 kDa | ||||
| Apparent Molecular Weight | Due to glycosylation, the protein migrates to 45-52 kDa based on Bis-Tris PAGE result. | ||||
| Formulation | Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). | ||||
| Reconstitution | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. | ||||
| Storage & Stability | Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles. |
The purity of Galectin 1 hFc Chimera, Mouse is greater than 95% as determined by SEC-HPLC. »
Galectin 1 hFc Chimera, Mouse on Bis-Tris PAGE under reduced condition. The purity is greater than 95%. »
| Target Background | Galectin 1(Gal-1), a β-galactoside binding mammalian lectin of 14KDa, is implicated in many signalling pathways, immune responses associated with cancer progression and immune disorders. Inhibition of human Gal-1 has been regarded as one of the potential therapeutic approaches for the treatment of cancer, as it plays a major role in tumour development and metastasis by modulating various biological functions viz. apoptosis, angiogenesis, migration, cell immune escape. |
| Synonyms | Galectin-1; HLBP14; S-Lac lectin 1; LGALS1; GAL1; GBP; DKFZp686E23103; Galectin 1 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.